ReviewFrontiers in immunology2026
Aryl hydrocarbon receptor regulates programmed cell death in diseases: molecular mechanisms and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aryl hydrocarbon receptor (AHR), which is a ligand-activated transcription factor, controls complex transcription programs in a ligand-specific, cell type-specific, and context-specific manner by integrating signals from the environment, diet, microorganisms, and metabolism. Emerging evidence indicates that AHR participates in the regulation of multiple cell death pathways, including apoptosis, necroptosis, autophagy, pyroptosis, and ferroptosis, playing a crucial role in influencing the pathogenesis of diseases. Originally identified as a sensor for environmental toxins, AHR is now recognized for its interactions with both endogenous and microbial ligands, allowing it to orchestrate complex biological processes. This review synthesizes current knowledge on the structural dynamics, ligand diversity, and activation mechanisms of AHR, while highlighting its dual roles in programmed cell death (PCD). Additionally, we discuss the significance of AHR-regulated cell death in inflammatory diseases, neurological disorders, respiratory diseases, and cancer, highlighting its potential as a therapeutic target for various human conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.